Michael Lim, MD
Interventional Cardiology · Hackensack, NJNPI 1235151861
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $159,870 of the $215,454 with a category attached, or 74.2%. Abiomed accounts for 62.9% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2020 at $63,214 and has fallen 80.3% since, to $12,455 in 2025. Among interventional cardiology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $619.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$135K
- ZOLL Circulation Inc$43K
- Amgen$19K
- Medtronic$7K
- Opsens Inc.$3K
- Abbott$2K
- plus $6K from 21 others
Across 7 payments — averaging $2313.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$16K
- ZOLL Circulation Inc$220
- Abiomed$24
What the payments were for
- Consulting fees$14,6507%
- Speaking & faculty fees$159,87074%
- Travel & lodging$25,66112%
- Food & beverage$15,2737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 127 | $135,455 |
| ZOLL Circulation Inc | 40 | $43,255 |
| Amgen | 20 | $19,156 |
| Medtronic(2 entities) | 35 | $7,208 |
| Opsens Inc. | 6 | $2,553 |
| Abbott | 21 | $1,759 |
| Boston Scientific | 34 | $1,409 |
| Saranas, Inc. | 11 | $726 |
| Shockwave Medical, Inc | 7 | $638 |
| Edwards Lifesciences | 10 | $633 |
| Medicure Pharma Inc. | 2 | $600 |
| Acist Medical Systems, Inc. | 3 | $435 |
| Siemens Medical Solutions USA, Inc. | 3 | $344 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $271 |
| Biosense Webster, Inc. | 4 | $252 |
| Cathworks, Inc. | 1 | $191 |
| Penumbra, Inc. | 3 | $143 |
| GE HealthCare | 1 | $104 |
| Chiesi USA, Inc. | 1 | $65 |
| Angiodynamics, Inc. | 2 | $52 |
| Recor Medical Inc | 1 | $45 |
| Philips North America LLC | 2 | $43 |
| Heartflow, Inc. | 1 | $35 |
| Valeritas, Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $23 |
| Stryker | 1 | $21 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$132,947
- Catheter$42,724
- TherOx DS2 Console$41,730
- Downstream Cartridge$41,730
- Repatha$18,920
- Resolute$5,013
- OptoWire$2,483
- OptoMonitor$2,483
- Temperature Management System$994
- Temperature Management System Start-Up Kit$994
- Tendyne Mitral Valve System$571
- Aggrastat (tirofiban HCl)$400
- Edwards SAPIEN 3 Transcatheter Heart Valve$351
- HD-IVUS$340
- Artis icono floor$327
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$299
- AVVIGO Guidance System$281
- Acute cardiovascular care$200
- FFRangio$191
- COREVALVE EVOLUT R$175
How this compares
$215,454 in reported general payments places this provider in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $48,068 |
| EntrestoSacubitril/Valsartan | 42 | $35,663 |
| BrilintaTicagrelor | 11 | $4,770 |
| Metoprolol Succinate | 122 | $1,171 |
| Ranolazine ErRanolazine | 15 | $1,020 |
| Atorvastatin Calcium | 90 | $661 |
| Potassium Chloride | 35 | $344 |
| Carvedilol | 36 | $336 |
| ClopidogrelClopidogrel Bisulfate | 45 | $321 |
| Losartan Potassium | 60 | $312 |
| Spironolactone | 55 | $272 |
| Amlodipine Besylate | 64 | $238 |
| Furosemide | 38 | $127 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $86 |
| Chlorthalidone | 11 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $48,06853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Hackensack
- Ryan KapleHackensack$178K
- Sung-Han YoonHackensack$105K
- Pranaychandra VaidyaHackensack$50K
- Hemal BhattHackensack$26K
- Justin LeeHackensack$13K
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Darshan GodkarCedar Knolls$194K
- Matthew SayboltEatontown$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.